Keratoacanthoma

  • 10min
  • May. 2022
  • Supported by
  • La Roche-Posay

Therapeutic classes inducing this adverse event
BRAF inhibitor, RAF inhibitor

Keratoacanthoma
Well-defined papule with central hyperkeratotic core, eruptive onset
Well-defined papule with central hyperkeratotic core, eruptive onset

Browse for more adverse events